

Clinical trial results:

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have Received a Liver Transplant Summary

Results information	
Trial information	
Trial identification	
Additional study identifiers	
Sponsors	
Paediatric regulatory details	
	1

Results analysis stage	
General information about the tri	ial
Population of trial subjects	
Subjects enrolled per country	
Subjects enrolled per age group	

Subject disposition	
Recruitment	
Pre-assignment	
Period 1	
Arms	
Arm title	
	1
Number of subjects in period 1	

Reporting groups Reporting group values

Baseline characteristics

End points reporting groups	
Primary: Percentage of Participa Weeks After Cessation of Therap	ents With Sustained Virologic Response (SVR) 12 by (SVR12)

End points

nd point values				
tatistical analyses				
Secondary: Percentage of P After Cessation of Therapy (articipants Wi (SVR4)	ith Sustained	Virologic Re	sponse 4 Weeks
nd point values				
Statistical analyses				
Statistical analyses				
Secondary: Percentage of P	articipants Wi	ith HCV RNA	< LLOQ at W	eek 2
-				
	1			
	<u></u>		<u></u>	

End point values				
	-			
Statistical analyses				
Secondary: Percentage of Partici	pants With H	CV RNA < LLO	OQ at Week 4	,
	Ι			
	l			
End point values				
-				
Statistical analyses				
Secondary: Percentage of Partici	pants With H	CV RNA < LLO	OQ at Week 8	
	1			

End point values				
Statistical analyses				
- Statistical analyses				
				_
Secondary: Percentage of Partici	pants With H	CV RNA < LLO	OQ at Week 1	2
End point values				
pomeranae				
Chatiatian I amplement				
Statistical analyses				
Secondary: HCV RNA at Week 2				

End point values		
Statistical analyses		
Secondary: HCV RNA at Week 4		
End point values		
Statistical analyses		
Secondary: HCV RNA at Week 8		
-		

	1					
End point values						
	•	•		•		
Statistical analyses						
Considerate HCV DNA of Wools 1	•					
Secondary: HCV RNA at Week 12	<u> </u>					
	1			-		
End point values						
Statistical analyses						
Secondary: Change From Baseli	ae in HCV DNA	at Week 2				
Secondary. Change From Baselin	THE ITT TICK KIND	at Week 2				
	1					
	1					

End point values					
Statistical analyses					
Secondary: Change From Baselin	e in HCV RNA	at Week 4			
- Secondary: Change From Baselin		THE WEEK 4			
	ı				
	Г				
	<u> </u>				
End point values					
Statistical analyses					
Secondary: Change From Baselin	e in HCV RNA	at Week 8			
Secondary: Change From Baselin		THE WEEK O			
	l				
	.				

End point values			
Statistical analyses			
- · · · · · · · · · · · · · · · · · · ·			
Secondary: Change From Baselin	e in HCV RNA	at Week 12	
	-		
	т		
End point values			
End point values			
Statistical analyses			
Statistical analyses			
Secondary: Percentage of Partici	nante With Vi	irologic Failu	
Secondary. Percentage of Partici		- In Ologic Fallul	
	l		

nd point values			
The point values			
	<u>'</u>		
Statistical analyses			

Adverse events Adverse events information Dictionary used Reporting groups Serious adverse events

Non-serious adverse events		

L		
-		

More information			
Substantial protocol amendments (globally)			
Interruptions (globally)			
Limitations and caveats			